BioSpace News Archive

High-throughput sequencing methods mainly based on Illumina platforms have benefited the entire field of biology for more than a decade.

Replimune Group, Inc. announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

Henry Schein, Inc. announced today the appointment of two executives – Trinh Clark and Leigh Benowitz – to the Company’s Executive Management Committee.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a virtual panel discussion entitled, “IOs Wide Open - Opportunity and Challenges in Immuno-Oncology” at the 2022 Wedbush PacGrow Healthcare Conference.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer,” based on work performed at the Crown Princess Mary Cancer Centre (“CPMCC”) at the University of Sydney, in Sydney, Australia.

Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced it will host a conference call on Monday, August 8, 2022, to discuss its second quarter 2022 financial results.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on August 1, 2022, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 290,500 shares of its common stock to Andrea Paul.

Coherus BioSciences, Inc., announced that effective August 1, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of the common stock of the Company to two newly hired employees with a per share exercise price of $9.16, the closing trading price on the grant date.